Vanguard Group Inc Codiak Bio Sciences, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.18 - $0.81 $43,733 - $196,802	-242,966 Reduced 29.5%	580,770 $104,000
Q4 2022 Feb 10, 2023	BUY	$0.32 - $0.9 $121 - $341	379 Added 0.05%	823,736 $329,000
Q3 2022 Nov 14, 2022	BUY	$0.82 - $3.19 $75,276 - $292,842	91,800 Added 12.55%	823,357 $644,000
Q2 2022 Aug 12, 2022	BUY	$2.24 - $6.96 $259,815 - $807,283	115,989 Added 18.84%	731,557 $2.11 Million
Q1 2022 May 13, 2022	SELL	$4.3 - $12.95 $289,691 - $872,441	-67,370 Reduced 9.86%	615,568 $3.86 Million
Q4 2021 Feb 14, 2022	BUY	$10.0 - $16.78 $200,800 - $336,942	20,080 Added 3.03%	682,938 $7.61 Million
Q3 2021 Nov 12, 2021	BUY	$15.58 - $22.88 $1.63 Million - $2.4 Million	104,833 Added 18.79%	662,858 $10.8 Million
Q2 2021 Aug 13, 2021	BUY	$11.72 - $26.81 $6.54 Million - $15 Million	558,025 New	558,025 $10.3 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.